Turning to operating expenses, selling general administrative expenses were $25 million in Q1 of 2026. compared with $24.3 million in Q1 of last year. This modest increase reflects discipline expense management, even as we continue to invest in technology, regulatory compliance infrastructure, and market expansion capabilities, including our AI-powered platform investments that Zorin will speak to in more detail.

Apr 28, 2026 / receipt, needs a key / Rich Christensen, CFO | earnings call 2026-04-28 | transcript bd04eec0-940c-49f6-abda-f5580e903d9d | chars 5233-5649 | segment 5

General and administrative expenses also include fees for professional services, mainly related to audit and legal services; consulting costs; communications and travel costs; allocated expenses for facility costs, including rent, utilities, and maintenance; directors’ attendance fees; and insurance costs.

filing / Apr 8, 2026 / receipt

Jean Volatier has served as our Chief Financial Officer since August 2012, and as our Deputy General Manager since January 2024.

filing / Apr 8, 2026 / receipt

Volatier has served as our Chief Financial Officer since August 2012, and as our Deputy General Manager since January 2024.

filing / Apr 8, 2026 / receipt

Moreover, any cost efficiencies that we previously hoped to gain by having confirmation of efficacy in a previously planned Part 2 of the NATiV3 trial will now be borne by a separate clinical outcome trial in MASH and compensated cirrhosis, such that it may ultimately take longer and cost more to get approved, if at all.

filing / Apr 8, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained.

filing / Apr 8, 2026 / receipt

Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.

filing / Apr 8, 2026 / receipt

36% decrease in R&D investment, €12.6 m vs €19.6 m in H1 19

ir_statement / Sep 15, 2026 / receipt

52% increase in R&D investment, €19.1 m vs €12.6 m in H1 20

ir_statement / Sep 15, 2026 / receipt

71% increase in G&A, €5.8 m vs €3.4 m in H1 20

ir_statement / Sep 15, 2026 / receipt

Monthly burn rate acceleration at €4.6 m in H1 21 vs €2.5 m in H1 20 (excluding R&D tax credit payments), heading towards c. €6.0 m per month in average by the end of 2021

ir_statement / Sep 15, 2026 / receipt

Major appointments to reinforce Inventiva’s clinical expertise, medical team and core corporate functions, as well as its presence in France and the United States

ir_statement / Sep 15, 2026 / receipt

The review of available options to optimize the development of odiparcil for the treatment of MPS VI continues and is now expected to conclude in 2022 (rather than in 2021 as previously anticipated)

ir_statement / Sep 15, 2026 / receipt